Allworth Financial’s ALX Oncology ALXO Stock Holding History

Allworth Financial’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10	Closed	–	–	2355
2022 Q1	$0	Buy	+10	New	+$171	﹤0.01%	2087

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Allworth Financial's ALXO Position: Q2 2022 in Review

Allworth Financial sold out of ALX Oncology (ALXO) in Q2 2022, closing a stake of 10 shares.

Allworth Financial first reported a position in ALXO in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 97 funds tracked by Wall St. Rank hold ALXO as of Q2 2022.

Allworth Financial reported no remaining ALX Oncology position as of Q2 2022 after selling out during the quarter.
Allworth Financial sold 10 ALX Oncology shares in Q2 2022.
Allworth Financial first reported a position in ALX Oncology in Q1 2022 and held it in 1 quarter.
Allworth Financial's ALX Oncology position peaked at $0 in Q1 2022.
97 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2022.

Based on Allworth Financial's 13F filing for Q2 2022, filed 13 Jul 2022.